Диссертация (1141216), страница 14
Текст из файла (страница 14)
- Сandida specialesСМЖ – спинномозговая жидкостьСМП – скорая медицинская помощьСПИД - синдром приобретённого иммунного дефицитаТБЦ - туберкулезХВГВ – хронический вирусный гепатит ВХВГС – хронический вирусный гепатит СЦМВ - цитомегаловирусная инфекция105СПИСОК ЛИТЕРАТУРЫ1. AIDSinfo Guidelines for Prevention and Treatment of Opportunistic Infectionsin HIV-Infected Adults and Adolescents // Guidelines for the Prevention and Treatmentof Opportunistic Infections in HIV-Infected Adults and Adolescents. 2017.2.
Alczuk S. de S.D. [и др.]. Effect of highly active antiretroviral therapy onvaginal Candida spp. isolation in HIV-infected compared to HIV-uninfected women. //Revista do Instituto de Medicina Tropical de Sao Paulo. 2015. № 2 (57). C. 169–74.3. Alexander B.D. [и др.]. Increasing Echinocandin Resistance in Candidaglabrata: Clinical Failure Correlates With Presence of FKS Mutations and ElevatedMinimum Inhibitory Concentrations // Clinical Infectious Diseases. 2013. № 12 (56).
C.1724–1732.4. Anwar K.P., Malik A., Subhan K.H. Profile of candidiasis in HIV infectedpatients. // Iranian journal of microbiology. 2012. № 4 (4). C. 204–9.5. Araújo D., Henriques M., Silva S. Portrait of Candida Species BiofilmRegulatory Network Genes // Trends in Microbiology. 2017. Т. 25. № 1. 62–75 с.6. Awoyeni A. [и др.]. Isolation and evaluation of Candida species and theirassociation with CD4+ T cells counts in HIV patients with diarrhoea. // African healthsciences. 2017. № 2 (17).
C. 322–329.7. Ben-Ami R. [и др.]. Heteroresistance to Fluconazole Is a ContinuouslyDistributed Phenotype among Candida glabrata Clinical Strains Associated with InVivo Persistence. // mBio. 2016. № 4 (7).8. Bonacini M., Young T., Laine L. The causes of esophageal symptoms inhuman immunodeficiency virus infection. A prospective study of 110 patients. //Archives of internal medicine. 1991. № 8 (151). C. 1567–72.9. Buttò S. [и др.]. Suggested strategies for the laboratory diagnosis of HIVinfection in Italy. // Annali dell’Istituto superiore di sanita.
2010. № 1 (46). C. 34–41.10. Cartledge J.D., Midgely J., Gazzard B.G. Itraconazole solution: higher serumdrug concentrations and better clinical response rates than the capsule formulation inacquired immunodeficiency syndrome patients with candidosis. // Journal of clinical106pathology. 1997. № 6 (50).
C. 477–80.11. Cartledge J.D., Midgley J., Gazzard B.G. Itraconazole cyclodextrin solution:The role of in vitro susceptibility testing in predicting successful treatment of HIVrelated fluconazole-resistant and fluconazole-susceptible oral candidosis // AIDS. 1997.№ 2 (11). C. 163–168.12. Clark-Ordóñez I. [и др.]. Candida species diversity and antifungalsusceptibility patterns in oral samples of HIV/AIDS patients in Baja California, Mexico.// Medical mycology. 2017.
№ 3 (55). C. 285–294.13. Daniell H.W. Acid suppressing therapy as a risk factor for C andidaesophagitis // Diseases of the Esophagus. 2016. № 5 (29). C. 479–483.14. Das P.P. [и др.]. Species distribution & antifungal susceptibility patternof oropharyngeal Candida isolates from human immunodeficiency virus infectedindividuals. // The Indian journal of medical research. 2016.
№ 4 (143). C. 495–501.15. Dodd C.L. [и др.]. Oral candidiasis in HIV infection: pseudomembranous anderythematous candidiasis show similar rates of progression to AIDS. // AIDS (London,England). 1991. № 11 (5). C. 1339–43.16. Enoch D.A. [и др.]. The changing epidemiology of invasive fungal infections// Methods in Molecular Biology. 2017. (1508). C.
17–65.17. Enwuru C.A. [и др.]. Fluconazole resistant opportunistic oro-pharyngealCandida and non-Candida yeast-like isolates from HIV infected patients attending ARVclinics in Lagos, Nigeria. // African health sciences. 2008. № 3 (8). C. 142–8.18. Epstein J.B., Truelove E.L., Izutzu K.T. Oral candidiasis: pathogenesis andhost defense // Rev Infect Dis.
1984. № 1 (6). C. 96–106.19. Feigal D.W. [и др.]. The prevalence of oral lesions in HIV-infectedhomosexual and bisexual men: three San Francisco epidemiological cohorts // AIDS.1991. № 5 (5). C. 519–525.20. Flowers S.A. [и др.]. Contribution of Clinically Derived Mutations in ERG11to Azole Resistance in Candida albicans // Antimicrobial Agents and Chemotherapy.2015.
№ 1 (59). C. 450–460.21. Fluit A.C. [и др.]. Antimicrobial susceptibility and frequency of occurrence107of clinical blood isolates in Europe from the SENTRY antimicrobial surveillanceprogram, 1997 and 1998. // Clinical infectious diseases : an official publication of theInfectious Diseases Society of America. 2000.
№ 3 (30). C. 454–60.22. Gago S. [и др.]. Candida parapsilosis, Candida orthopsilosis, and Candidametapsilosis virulence in the non-conventional host Galleria mellonella // Virulence.2014. № 2 (5). C. 278–285.23. Gaitán-Cepeda L.A., Sánchez-Vargas O., Castillo N. Prevalence of oralcandidiasis in HIV/AIDS children in highly active antiretroviral therapy era. A literatureanalysis // International Journal of STD & AIDS.
2015. № 9 (26). C. 625–632.24. Greenberg R.G., Berger T.G. Nail and mucocutaneous hyperpigmentationwith azidothymidine therapy // Journal of the American Academy of Dermatology.1990. № 2 (22). C. 327–330.25. Hartz A.S., Cury A. E. C.O.F. Candida albicans from aids patients,Susceptibility in vitro to antifungal agents // Rev.Microbiol.
1992. № 2 (23). C. 133–135.26. Hoffmann C. [и др.]. Archaea and fungi of the human gut microbiome:correlations with diet and bacterial residents. // PloS one. 2013. № 6 (8). C. e66019.27. Holmstrup P S.L. Acute and AIDS-related oral candidosis. London, 1990.28. Hoog G.S. de, Guarro J.
G.J. et al. Atlas of clinical fungi: electronic version3.1. // 2011.29. Huseyin C.E. [и др.]. Forgotten fungi—the gut mycobiome in human healthand disease // FEMS Microbiology Reviews. 2017. № 4 (41). C. 479–511.30. JJ P. Oral candidiasis in HIV infection / P. JJ, 1988. 23 c.31. Johnson E.M. [и др.]. Emergence of azole drug resistance in Candida speciesfrom HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.// The Journal of antimicrobial chemotherapy. 1995. № 1 (35).
C. 103–14.32. Katiraee F., Teifoori F., Soltani M. Emergence of Azoles Resistance Candidaspecies in Iranian AIDS defined patients with oropharyngeal candidiasis // CurrentMedical Mycology. 2015. № 3 (1). C. 11–16.33. Katz M.H. [и др.]. Progression to AIDS in HIV-infected homosexual and108bisexual men with hairy leukoplakia and oral candidiasis // AIDS.
1992. № 1 (6). C. 95–100.34. Kelly M.N. [и др.]. Memory CD4+ T cells are required for optimal NK celleffector functions against the opportunistic fungal pathogen Pneumocystis murina. //Journal of immunology (Baltimore, Md. : 1950). 2013. № 1 (190). C. 285–95.35. Klein R.S. [и др.]. Oral candidiasis in high-risk patients as the initialmanifestation of the acquired immunodeficiency syndrome. // The New England journalof medicine. 1984.
№ 6 (311). C. 354–8.36. Kraneveld E.A. [и др.]. The relation between oral Candida load and bacterialmicrobiome profiles in Dutch older adults. // PloS one. 2012. № 8 (7). C. e42770.37. Kwamin F. [и др.]. Distribution of Candida species among HIV-positivepatients with oropharyngeal candidiasis in Accra, Ghana. // Journal of infection indeveloping countries. 2013. № 1 (7). C. 41–5.38.LiX.[идр.].OropharyngealCandidacolonizationinhumanimmunodeficiency virus infected patients // APMIS.
2013. № 5 (121). C. 375–402.39. Lima G.M.E. [и др.]. Identification and antifungal susceptibility of Candidaspecies isolated from the urine of patients in a university hospital in Brazil. // Revista doInstituto de Medicina Tropical de Sao Paulo. 2017. (59). C. e75.40. Liu F. [и др.]. Sequential Dysfunction and Progressive Depletion of Candidaalbicans-Specific CD4 T Cell Response in HIV-1 Infection. // PLoS pathogens.
2016. №6 (12). C. e1005663.41. Martins N. [и др.]. Candidiasis: Predisposing Factors, Prevention, Diagnosisand Alternative Treatment // Mycopathologia. 2014. № 5–6 (177). C. 223–240.42. Mas J., PinA E. Disappearance of Nystatin Resistance in Candida Mediatedby Ergosterol // Microbiology. 1980. № 1 (117). C. 249–252.43. Mathé L., Dijck P. Van Recent insights into Candida albicans biofilmresistance mechanisms // Current Genetics. 2013.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
